Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 7;13(11):2051. doi: 10.3390/genes13112051

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

SPOP mRNA expression in different cancers. (a) A graph showing the levels of SPOP mRNA expression levels in a variety of cancers along with corresponding normal controls; BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; CHOL, Cholangiocarcinoma; COAD, Colon Adenocarcinoma; ESCA, esophageal carcinoma; HNSC, Head and Neck squamous cell carcinoma; KICH, Kidney Chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PAAD, Pancreatic adenocarcinoma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine Corpus Endometrial Carcinoma; ns, not significant; * p < 0.05, ** p < 0.01, *** p < 0.001. (b) SPOP alterations occur across multiple cancer types (data from the cBioPortal database). (c) The correlation of SPOP with overall survival is further elevated (data from the The Cancer Genome Atlas (TCGA) portal or other published datasets of clinical cancer samples as indicated).

SPOP mRNA expression in different cancers. (a) A graph showing the levels of SPOP mRNA expression levels in a variety of cancers along with corresponding normal controls; BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; CHOL, Cholangiocarcinoma; COAD, Colon Adenocarcinoma; ESCA, esophageal carcinoma; HNSC, Head and Neck squamous cell carcinoma; KICH, Kidney Chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PAAD, Pancreatic adenocarcinoma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma; UCEC, Uterine Corpus Endometrial Carcinoma; ns, not significant; * p < 0.05, ** p < 0.01, *** p < 0.001. (b) SPOP alterations occur across multiple cancer types (data from the cBioPortal database). (c) The correlation of SPOP with overall survival is further elevated (data from the The Cancer Genome Atlas (TCGA) portal or other published datasets of clinical cancer samples as indicated).